Merck, Inc.

DelveInsight's 'Glioblastoma Pipeline Insight, 2024' report details 190+ companies developing 200+ therapies, including Enzastaurin, Marizomib, VT1021, and ONC201, with insights on mechanism of action, route of administration, and market dynamics.

Lupin receives tentative U.S. FDA approval for Raltegravir tablets, potentially securing 180-day exclusivity for a generic version of Merck’s Isentress HD. The drug, manufactured at Lupin’s Nagpur facility, treats HIV-1 infection and is expected to impact the $36 million U.S. market.

Lupin Limited received tentative FDA approval for its generic raltegravir tablets USP, 600 mg, equivalent to Merck's Isentress HD. Lupin is the exclusive first-to-file and may receive 180-day exclusivity. The product treats HIV-1 in adults and pediatric patients weighing at least 40 kg, with an estimated annual US sales of USD 36 million.

In a phase II study, lenvatinib added to ifosfamide/etoposide did not significantly improve progression-free survival in children or young adults with relapsed or refractory osteosarcoma. Median progression-free survival was 6.5 months in the lenvatinib group vs 5.5 months in the control group. The study highlights the importance of international collaboration and randomized clinical trials in this patient population.

Adjuvant atezolizumab and nivolumab showed no significant DFS or OS improvement in RCC post-nephrectomy, while pembrolizumab significantly improved DFS and OS. Ongoing trials with durvalumab and belzutifan plus pembrolizumab aim to further enhance survival outcomes in RCC.

DelveInsight's 'Melanoma Pipeline Insight 2024' covers 150+ companies and 170+ pipeline drugs, including IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, and BioNTech SE. Key therapies like Amtagvi (Iovance Biotherapeutics) received FDA fast-track approval in 2024 for metastatic melanoma. Neoadjuvant immunotherapy became standard care for stage III melanoma after ESMO 2024 updates. The report assesses therapies by product type, stage, route of administration, and molecule type, highlighting active and inactive pipeline products.

Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D, indicating FYB206 is structurally and functionally highly similar to Keytruda®, supporting ongoing clinical trials.

DelveInsight's report on Congestive Heart Failure Market (2020-2034) covers epidemiology, market trends, key companies, and therapies. Market size was ~USD 6,900 million in 2023, expected to grow significantly. Key companies include Novartis, Bayer, and Eli Lilly. Therapies like ENTRESTO and JARDIANCE are highlighted. Market drivers include aging population and disease prevalence, while barriers include generic therapies and diagnostic challenges.

Tau Inhibitors Clinical Trial Pipeline Analysis shows 25+ key companies expected to transform treatment, with increased funding accelerating advancements in neurodegenerative disease therapies.

Phanes Therapeutics announced the first patient dosed in the PT886 clinical study combined with Merck's KEYTRUDA® for gastric and gastroesophageal junction cancers. PT886, a first-in-class bispecific antibody, targets claudin 18.2 and CD47, and is being evaluated in various cancer treatments.